While RIT with either 177Lu and 225Ac isotope alone provided little therapeutic advantage, a profound anti-tumor effect was achieved, and improved survival was observed when low-dose 177Lu RIT was combined with anti-PD-1 ICB therapy (Table 1). The gene discussed is PDCD1; the disease is neoplasm.